A controlled study of pregabalin combined with escitalopram in patients with major depressive disorder

Corresponding author: Yin Junbo, qdyjb9131@163.com

DOI: 10.12201/bmr.202501.00017

•  

  Abstract: Abstract: To explore the clinical efficacy and safety of escitalopram combined with pregabalin in patients with major depressive disorder. Methods: Sixty patients with recurrent depression were selected and divided into an experimental group (pregabalin combined with escitalopram, n = 30) and a control group (escitalopram, n = 30). The treatment course was 6 weeks. Before treatment and at the 2nd, 4th, and 6th weeks of treatment,Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA), and Treatment Emergent Symptom Scale (TESS) were used to evaluate efficacy and safety. Results: Before enrollment, there was no statistically significant difference in the scores of HAMD-17 and HAMA between the two groups (t = 0.615, P > 0.05).The scores after 2, 4, and 6 weeks of treatment were all lower than those before treatment. At the end of the 2nd week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 4th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). At the end of the 6th week after treatment, the HAMD-17 and HAMA scores of the experimental group were lower than those of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Pregabalin combined with escitalopram can relieve anxiety symptoms and have antidepressant efficacy more quickly and effectively in patients with MDD.

  Key words: Pregabalin; Escitalopram; Major Depressive Disorder; Generalised anxiety disorder

  Submit time: 6 January 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• CHEN Manman, TENG Yuxin, ZENG Botao. Study on self-injurious and suicidal behavior, non-enzymatic antioxidants and thyroid hormones in adolescents with depressive disorder. 2024. doi: 10.12201/bmr.202412.00022

  YU Feng, ZOU Xiao-jie, XU Zhen. The relationship between hyperactivity behavior in children with attention deficit hyperactivity disorder and serum levels of thyroid-stimulating hormone. 2024. doi: 10.12201/bmr.202411.00024

  YANG Qing. Clinical Observation of Qinggan Ningxin Zhidong Prescription in the Treatment of Attention Deficit Hyperactivity Disorder with Heart-Liver Fire Blazing Syndrome. 2024. doi: 10.12201/bmr.202412.00051

  fengxiaojuan, liyang, yanzihui, fanzhiliang. A Study on the Psychological Health Status of Migraine Patients. 2024. doi: 10.12201/bmr.202408.00034

  Wang Yeliu, Zhou Shuping. Clinical efficacy and safety of Esomeprazole combined with Biling Weitong granules in the treatment of EPS. 2025. doi: 10.12201/bmr.202501.00052

  ma guang fan, chen xiao zhen, zhou sen. Effect of esketamine on early postoperative mental state in patients with breast cancer. 2024. doi: 10.12201/bmr.202412.00054

  DU Ben-feng, GENG Rui, MU Yue-xuan, HAO Xin, WANG Jing-wen. Childhood Family Dysfunction and Depression in the Elderly: Impact Contribution, Cumulative Effect and Influence mechanism. 2022. doi: 10.12201/bmr.202111.00022

  HU Linlin, ZHANG Yonghua. Study on early intervention of insomnia in depression treated by TCM syndrome differentiation. 2024. doi: 10.12201/bmr.202408.00051

  shaojie. Research progress on environmental factors of autism spectrum disorders in children. 2024. doi: 10.12201/bmr.202410.00005

  Yang min. Study on the Treatment of Coagulation Dysfunction and Limb Swelling after Bloodborne Venom Snake Bite with Hyperbaric Oxygen Combined with External Use of Snake Damage Powder. 2024. doi: 10.12201/bmr.202407.00060

• ID	Submit time	Number	Download
  1	2024-12-07	bmr.202501.00017V1	Download

• Public  Anonymous  To author only Submit Comments